Microbiotica
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Chesterford Research Park Little Chester...Phone Number
+44 2078667860Website
www.microbiotica.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Microbiotica
Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform. Consisting of the leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica's platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company's current therapeutic areas of focus are immuno-oncology and IBD and it has established major clinical and academic partnerships in these areas. Spun out of the Sanger Institute in 2016, the Company is based at Chesterford Research Park near Cambridge, UK. Microbiotica's investor syndicate includes British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners, and TeRead more
Microbiotica Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Microbiotica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Microbiotica launches new products
Click to see if Microbiotica had a recent Job posting/layoffs
Check out if Microbiotica is spiking on competitors!
Microbiotica, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Microbiotica
Website visits: Recent activity has been detected on your website
Check if Microbiotica has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Microbiotica recently announced quarterly report
Funding: Get notified immidiatlly once Microbiotica has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Microbiotica
Compare insights from companies similar to Microbiotica, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Microbiotica is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Microbiotica is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Microbiotica.
Microbiotica financials insights
Gather financial insights about Microbiotica, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Multiple Rounds
$201M
Microbiotica Tech Stack
A closer look at the technologies used by Microbiotica
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Promotion
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Promotion
Executive Move
Microbiotica News & Media
Investor joins Microbiotica as CMO | The Pharmaletter
UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO).Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier
Data presented at Digestive Disease Week in San Diego Data presented at Digestive Disease Week in San DiegoMicrobiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
Data presented at AACR Annual Meeting in Chicago Data presented at AACR Annual Meeting in ChicagoMicrobiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
Data presented at AACR IO meeting in Los Angeles Data presented at AACR IO meeting in Los Angeles
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Microbiotica
Sign Up For FreeTo access detailed company insights
Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform. Consisting of the leading microbiome Referen... Read More
